Vaxxas Advances Needle-Free Vaccine Technology with $100 Million Funding

Brisbane-based biotechnology company Vaxxas is set to revolutionize vaccine delivery through its high-density microarray patch (HD-MAP) technology, which administers vaccines via thousands of microscopic projections on a small patch applied to the skin. This method aims to enhance vaccine performance and address logistical challenges associated with traditional needle-and-syringe methods. The company has successfully completed five Phase I clinical trials involving over 500 participants for vaccines targeting COVID-19, influenza, and measles-rubella. Currently, Vaxxas is conducting a U.S. Phase I clinical study for a pre-pandemic influenza vaccine, funded by the Biomedical Advanced Research and Development Authority. To support further trials and global expansion, Vaxxas has raised $100 million and secured patents in the U.S., Europe, and Asia. The company plans to manufacture and distribute its vaccine patches worldwide from its Brisbane headquarters within the next three to five years.

Vaxxas’s vaccine technology would particularly enhance delivery of mRNA vaccines, which represent an incredible achievement in the application of genomic technology in medicine and public health over the past half-decade. The COVID-19 vaccine was one of the first mRNA vaccines, and that technology is now being applied across a wide range of uses.

For more information, read the full news story on InDaily Queensland’s website.

Stay informed about the latest developments in genomics by following InGeNA for updates on the global genomics industry.